At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 60 enrolled
Drug / intervention
Lanabecestat +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of LY3314814 on the Pharmacokinetics of Dabigatran in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating Lanabecestat and Dabigatran etexilate for Healthy. Completed, enrolled 60 participants across 1 site.
Detailed Summary
The purpose of this study is to learn about the effect of lanabecestat on how the body absorbs and processes dabigatran etexilate and how dabigatran etexilate affects lanabecestat when they are taken together. This study will last about 28 days and participants will be asked to take an lanabecestat tablet daily for 19 days and a dabigatran etexilate tablet on 3 occasions. Screening is required within 30 days prior to the start of the study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsEli Lilly and Company
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 2015
Enrollment StartOct 2015
Primary CompletionJan 2016
TodayJul 2026
First PostedOct 5, 2015
Enrollment StartOct 31, 2015
Primary CompletionJan 31, 2016
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 10.7 years ago
Interventions
Lanabecestatdrug
Administered orally
Dabigatran etexilatedrug
Administered orally